Signals provided by the erythropoieitin receptor (EpoR) are required for erythroid development beyond the erythroid colonyforming unit (CFU-e) stage and are propagated via the EpoR-tethered Janus kinase, JAK2. JAK2 functions, in part, to phosphorylate 8 conserved EpoR phosphotyrosine (PY) sites for the binding of a diverse set of signaling factors. However, recent studies in transgenic and knock-in mice have demonstrated substantial bioactivity for PY-null EpoR forms. Presently, the activities of a PY-null EpoR-HM form in primary progenitor cells from knock-in mice were further assessed using optimized Epo dose-dependent proliferation, survival, and differentiation assays. As compared with the wild-type (wt)-EpoR, EpoR-HM activity was compromised several-fold in each context when Epo was limited to physiologic concentrations. Possible compensatory increases in serum growth factor levels also were investigated, and as assayed using embryonic stem (ES) cell-derived erythroid G1E2 cells, activities in serum from EpoR-HM mice were substantially elevated. In addition, when challenged with phenylhydrazine-induced anemia, EpoR-HM mice failed to respond with efficient splenic stress erythropoiesis. Thus, the function of this JAK2-coupled but minimal PY-null EpoR-HM form appears to be attenuated in several contexts and to be assisted in vivo by compensatory mechanisms. 
Introduction
The cell surface receptors for several clinically important colonystimulating factors and interleukins form a type 1 receptor superfamily. 1, 2 Common features include (1) extracellular 2-fold 7 ␤-strand FNIII subdomains that function in ligand binding 3, 4 ; (2) an approximately 50 amino acid juxamembrane cytoplasmic box 1 domain 5, 6 in ␤-and ␥-chains that tethers these receptors to Janus kinase (JAK) protein tyrosine kinases; 7, 8 and (3) the occurrence (especially in receptor ␤-chains) of cytoplasmic tyrosine sites that are phosphorylated by JAKs and function as docking sites for diverse sets of SH2 domain-encoding signal transduction factors. 9, 10 Investigations using box 1 region mutants, 11, 12 dominantnegative JAKs, 13, 14 and/or mice with JAK kinase gene disruptions 15, 16 have revealed the essential nature (and upstream positioning) of JAKs in several type 1 receptor systems. For at least certain cytokine receptors, studies of phosphotyrosine (PY) site function also have pointed to important contributing roles for at least select PY sites (and coupled transduction pathways). Examples include key roles for PY440 of the interferon-␥ receptor-1 chain in engaging signal transducer and activator of transcription-1 (Stat1) and interferon (IFN) response pathways 17, 18 and for a PY704 Stat3 (and/or Stat1) binding site in the granulocyte colonystimulating factor (G-CSF) receptor, which recently has been shown to be critical for neutrophil function in a targeted transgenic mouse model. 19, 20 For other receptors, however, controversy exists regarding the relative functional importance of PY sites and linked events, and meaningful bioactivity has been shown to be exerted by receptor forms that couple to JAK kinases but lack cytoplasmic PY sites. 21, 22 Effects of stimulating JAK2-only pathways also have been probed in cell line models 23, 24 and recently in primary cells via the ectopic expression of JAK2 catalytic domain constructs. 25 For example, EpoR-JAK2 and epidermal growth factor (EGF) receptor-JAK2 chimeras have been shown to promote proliferation in FDCP1 and 32D cells 23, 24 as has an AP20187 binding site-JAK2 catalytic domain fusion construct in BaF3 cells. 25 In primary hematopoietic cells, this latter construct interestingly cofunctions selectively with either stem cell factor (SCF) or Flt3 ligand to promote early hematopoietic progenitor cell expansion with Stat5 dependency. 25 In the case of the erythropoietin receptor (EpoR), biofunction of PY-null receptor forms recently has been demonstrated in transgenic 26, 27 as well as knock-in mouse models. 28 Specifically, our laboratory has expressed PY-containing and PY-null EpoR forms in transgenic mice from a Gata1 gene vector (as hEGF receptor-EpoR EE chimeras) and has reported on the high activity of a Stat5-coupled PY343-containing form and compromised activity in growth and differentiation assays of a derived Y343F PY-null EpoR form. 26, 27 By comparison, Zang et al 28 have studied essentially equivalent EpoR forms via their introduction into the endogenous EpoR locus. Based on in vivo performance and colony-forming assays, a Y343-retaining EpoR-H form possessed similarly elevated activities, while a PY-null form (EpoR-HM) was somewhat less active than wild-type (wt)-EpoR controls but overall conferred only mild in vivo biosignaling defects. In the present studies, bioactivities of this knocked-in PY-null EpoR-HM form have been analyzed further through the optimization of Epo dose-dependent in vitro assays for EpoR-supported primary adult erythroid progenitor cell proliferation, differentiation, and survival. Studies reveal Epo dose-dependent deficiencies in the activities of this JAK2-coupled but PY-null EpoR form in each context. In addition, in vivo analyses also reveal not only elevated serum growth factor activity in EpoR-HM mice but, also, compromised stress-induced erythropoiesis. Together, these findings indicate that at least certain EpoR PY-coupled events can contribute in important ways to a core EpoR-JAK2 signaling axis.
Materials and methods

Mice
EpoR-HM mice expressing a targeted transgenic PY-null EpoR form from the endogenous EpoR gene were those developed by Zang et al. 28 These and control wild-type EpoR C57BL/6 mice (Charles River Laboratories, Wilmington, MA) used in experiments were 6 to 8 weeks old. Genomic polymerase chain reaction (PCR) with primers 5Ј-GAGTTT-GAGGGTCTCTTCACC-3Ј (exon 7) and 5Ј-TAGGCTGGAGTCCTAG-GAGC-3Ј (exon 8) was used to confirm genotypes. In stress erythropoiesis experiments, phenylhydrazine (Sigma, St Louis, MO) was injected subcutaneously (60 mg/kg) at 0 and 24 hours.
Marrow and spleen cell preparations
Progenitor cells were prepared from bone marrow as described. 29 Specifically, mice were humanely killed with CO 2 , femurs and tibiae were isolated, and marrow cells were gently flushed from cavities using 21ga (femur) or 23ga (tibia) needles with a total volume of 10 mL (per mouse) Iscove modified Dulbecco medium (IMDM) plus 2% fetal bovine serum (FBS). Cells then were passed thrice slowly through a 21ga needle and a 70-m strainer; were collected and resuspended initially in 1 mL of 138 mM NaCl, 2.7 mM KCl, 1.2 mM KH 2 PO 4 , 8.1 mM Na 2 HPO 4 , pH 7.4 (phosphatebuffered saline [PBS]); and were exposed for 2 minutes to 9 mL potassium bicarbonate-buffered 0.8% ammonium chloride, 0.1 mM Na 2 EDTA (ethylenediaminetetraacetic acid) solution, pH 7.5. 10 ϫ PBS (1.1 mL) was added, and cells were collected through 15 mL of 50% FBS in PBS, washed in IMDM plus 2% FBS, and resuspended initially in 1.5 mL hematopoietic cell expansion medium (HCEM) as IMDM supplemented with 0.75% bovine serum albumin (BSA), 7.5 g/mL insulin, 150 g/mL iron-saturated human transferrin (Stem Cell Technologies, Vancouver, BC), 0.1 mM ␤-mercaptoethanol, 12% FBS (catalog no. SH30070; HyClone, Logan, UT), plus penicillin (100 U/mL), streptomycin (100 g/mL), and amphotericin B (0.25 g/mL) (PSF). In cell counts, cells (0.1 mL) were exposed for 2 minutes to 3% acetic acid (3.9 mL) and 0.44 mL of 10-fold concentrated PBS was added. These cells (0.5 mL) then were combined with precisely 10 5 fluorospheres (catalog no. 752410F; Coulter, Miami, FL) in 0.5 mL PBS. Cells numbers (per milliliter) then were determined via flow analysis of 10 000 microsphere events (and were confirmed via direct manual counting). Splenocytes were prepared at 120 hours after phenylhydrazine injection as detailed by Zhang et al. 30 
HdT incorporation assays
Marrow preparations were adjusted in HCEM to 1 ϫ 10 6 cells per milliliter and plated (50 L per well 31 and at 24 and 48 hours, equal volumes of new medium were added. In Epo-dependent proliferation assays, dexamethasone, ␤-estradiol, SCF, and Epo were omitted, and washed cells were plated at 5 ϫ 10 5 per milliliter. Rates of Epo-dependent 3 H-thymidine ( 3 HdT) incorporation then were assayed at 24 hours of culture.
Assays of Ter119, CD71, and phosphatidylserine (PS) expression
Marrow preparations at 1 ϫ 10 6 cells per milliliter were cultured in HCEM supplemented with Epo at indexed concentrations. Epo-dependent Ter119-positive cell formation was assayed using a phycoerythrin (PE)-Ter119 antibody (BD-Pharmingen, San Diego, CA), and transferrin receptor expression was assayed using a fluorescein isothiocyanate (FITC) anti-CD71 antibody (BD-Pharmingen). Assays involved stepwise 4°C incubations of washed cells in 0.3 mL PBS, 0.1% BSA with murine immunoglobulin G (IgG) Fc fragment (5 g; Pierce Biotechnology, Rockford, IL) for 30 minutes and with PE-Ter119 (1 g) and/or FITC-anti-CD71 antibody (2 g) for 45 minutes. In annexin V binding assays, Ter119-stained cells were incubated for 45 minutes in 0.3 mL of 140 mM NaCl, 2.5 mM CaCl 2 10 mM HEPES (N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid)/NaOH, pH 7.4, with 5 L FITC-annexin V (catalog no. 65874X; BD-Pharmingen) and were washed in this buffer prior to flow cytometry (Coulter XL system).
TUNEL assays
Marrow preparations were cultured in HCEM with Epo at 1.6, 0.1, or 0 U/mL, and at 42 hours, levels of apoptotic Ter119-positive cells were assayed using a DeadEnd fluorometric terminal deoxyuridine triphosphate nick-end labeling (TUNEL) system (Promega, Madison, WI). In brief, 10 7 cells were washed in PBS, 0.5% BSA; were resuspended in 0.5 mL PBS; and were incubated at 4°C for 20 minutes with 5 mL of 1% MeOH-free formaldehyde in PBS (Polyscience, Niles, IL). Cells then were washed in PBS, 0.5% BSA; incubated for 5 minutes at 4°C in 5 mL of 0.2% Triton X-100 in PBS; and washed in PBS, 0.5% BSA. In TUNEL reactions, cells were incubated at 37°C for 60 minutes in 45 L equilibration buffer, 5 L nucleotide mix, and 1 L (10 units) terminal deoxynucleotidyl-transferase. Reactions were terminated (by the addition of 1 mL of 20 mM Na 2 EDTA, pH 8.0), and cells then were washed; resuspended in 0.3 mL PBS, 0.5% BSA; and stained with PE-Ter119.
Assays of serum growth factors activity
Whole blood (0.3 mL) was obtained by cardiac puncture and was used to prepare sterile plasma. Growth factor activity in samples from 8-week-old EpoR-HM and C57BL/6 mice then was assayed using embryonic stem (ES) cell-derived G1E2 cells. 32 G1E2 cells were maintained in IMDM, 12% FBS, 0.1 mM monothioglycerol, PSF, 50 ng/mL mSCF, and 2 U/mL Epo. In proliferation assays, mSCF was decreased to 10 ng/mL, Epo was omitted, and cells (at 5 ϫ 10 5 /mL) were challenged with plasma at increasing concentrations. 3 HdT incorporation rates were determined at 24 hours of culture.
Results
Epo dose-dependent deficiencies in EpoR-HM signaling of erythroid progenitor cell proliferation, survival, and differentiation
Pilot experiments first sought to develop a useful Epo dosedependent proliferative response assay using marrow cell preparations from adult mice. In assays of Epo-dependent erythroid progenitor cell (EPC) differentiation (Figure 2 ), the development of Ter119-positive cells from these primary preparations occurred at meaningful frequencies within 28 hours of culture. From this it was predicted that normal marrow might contain well-represented cohorts of Ter119 Ϫ yet Epo-responsive EPCs. This was tested by 3 HdT pulse-labeling of Epo-exposed primary marrow cell preparations at early culture intervals ( Figure 1A) . At approximately 14 hours of culture, Epo-induced 3 HdT incorporation rates were relatively high but subsequently decreased during EPC maturation. By comparison, rates of IL-3-stimulated 3 HdT incorporation were low at early time points but then markedly increased. Useful Epo dose-response profiles also were obtained at 14 hours of culture. When this assay was used to compare EpoR-HM versus wt-EpoR activities in primary EPCs, several-fold decreases in 3 HdT incorporation rates were observed for EPCs from EpoR-HM mice ( Figure  1B-C) . To extend this finding, EPCs also were cultured in the presence of dexamethasone to inhibit differentiation and to expand SCF-and Epo-dependent EPCs. 31 Expanded cells then were plated at equivalent densities (in the absence of dexamethasone, ␤-estradiol, and SCF) and were challenged with Epo. EPCs from EpoR-HM mice again were significantly attenuated in their ability to support 3 HdT incorporation rates in response to physiological concentrations of Epo ( Figure 1D ).
As EPCs develop beyond the erythroid colony-forming unit (CFU-e) stage, a lineage-and stage-specific cell surface antigen, Ter119, is expressed that is thought to occur in association with glycophorin A. 33 This Epo-dependent developmental event was used to establish a second quantitative Epo bioassay. First, a time course for Ter119-positive cell formation from normal marrowderived EPCs was defined ( Figure 2A , left panel), and maximum frequencies of Ter119-positive cells were observed to develop within 42 hours of culture. The Epo concentration-dependent nature of this response also was defined (Figure 2A , right panel) and at 0.4 U/mL and 0.1 U/mL was limited to submaximal levels. This optimized assay next was used to study the Epo dosedependent EPCs from EpoR-HM and wt-EpoR mice. As Epo was limited from 1.6 to 0.4 to 0.1 U/mL, an attenuated ability of PY-null EpoR-HM receptors to support Ter119-positive EPC formation was discovered ( Figure 2B-C) . At an Epo concentration of 0.1 U/mL (and as corrected for background levels of Ter119-positive cells) the efficiency of EpoR-HM signaling of this response was 3.4-fold below that of the wt-EpoR. In Epo at 0.4 U/mL and 1.6 U/mL, this defect was reversed with near wild-type activity observed for EpoR-HM at 1.6 U/mL. To possibly more narrowly define the stage(s) of EPC development that might be most affected by deficient EpoR-HM signaling, cells cultured in Epo at 0.1, 0.4, and 1.6 U/mL were costained with PE-Ter119 and FITC-anti-CD71 antibodies (at a penultimate stage of erythropoiesis, CD71 levels sharply increase). Costaining resolved a subpopulation of early Figure 3A) . Analyses of the frequencies of these CD71 high to CD71 low subpopulations as they formed from EPCs isolated from EpoR-HM mice (versus wt-EpoR mice) revealed an attenuated ability of EpoR-HM to support CD71 low , Ter119-positive EPC formation. This finding also was analyzed as the ratios of these cell subtypes at varied Epo doses ( Figure 3C ). In addition, these differently staged Ter119-positive EPCs were isolated by fluorescence-activated cell sorting (FACS), and CD71 high EPCs were observed to correspond to proerythroblasts and basophilic erythroblasts, while derived CD71 low EPCs correspond to chromatophilic erythroblasts ( Figure 3B ). In Figure 4 , direct values for Epo dose-dependent Ter119-positive cell formation from EpoR-HM versus wt-EpoR EPCs are summarized for assays using 10 mice.
PY-NULL EPO RECEPTOR SIGNALING DEFECTS
The EpoR is also known to promote red cell production by inhibiting EPC apoptosis. 34 For Ter119-positive cells as they develop from EPCs in the above expansion system, frequencies of potentially apoptotic cells therefore also were assayed based initially on the staining of cell surface PS moieties with FITCannexin V (Figure 5A-C) . Clear Epo concentration-dependent differences were observed in annexin V staining of EpoR-HM Ter119-positive EPCs, and at an Epo dose of 0.1 U/mL levels of annexin V-negative cells were 3-fold greater for wt-EpoR EPCs (14.7%) than for EpoR-HM EPCs (45%). In Figure 6 , overall outcomes for 2 independent Epo dosing and annexin V staining experiments are summarized. Annexin V previously has been used to assay apoptotic cells in Ter119-positive splenocytes from phenylhydrazine-treated mice. 35 However, plasma membrane phospholipid compositions are modulated during red cell development, 36 and differences in annexin V staining of EPCs from EpoR-HM versus wt-EpoR mice might, in part, reflect altered development. Apoptosis among Ter119-positive cells from EpoR-HM and control wt-EpoR mice therefore was also assayed by TUNEL (Figure 7) . At an Epo dose of 0.1 U/mL (and at 42 hours culture), frequencies of TUNEL-positive Ter119-positive EPC cells from EpoR-HM mice were increased approximately 2-fold over wt-EpoR EPCs. At a high Epo dose (1.6 U/mL) this apparent defect in EPC survival was reversed, and this is in keeping with physiologic dose-response profiles observed in analyses of Epodependent EPC proliferation and development.
In EpoR-HM mice, serum growth factors are elevated and stress erythropoiesis is compromised
The limited ability of the PY-null EpoR-HM receptor form to support EPC development in the presence of Epo at limiting concentrations suggests that the in vivo function of this receptor form might be assisted by compensatory mechanisms. To test this basic hypothesis, serum was isolated from adult age-and sex-matched EpoR-HM and wt-EpoR mice and was assayed for activity in promoting the proliferation of an ES cell-derived erythroid cell line, G1E2. For serum samples from all EpoR-HM mice analyzed, significant increases in activity (stimulated 3 HdT incorporation) were discovered (Figure 8 ). Available systems for the immunoassay of murine Epo 37 proved to be quite variable, and the extent to which elevated Epo levels might account for increases in EpoR-HM serum growth factor activity presently is uncertain.
Again based on the above-observed attenuated Epo dosedependent in vitro development of EpoR-HM EPCs, we also investigated whether in vivo erythropoiesis also might be perturbed due to stress. Here, EpoR-HM and control wt-EpoR mice were treated with phenylhydrazine (60 mg/kg at 0 and 24 hours), and at 120 hours increases in splenic erythropoiesis due to induced hemolytic anemia were analyzed. As expected, spleens from wt-EpoR mice were increased markedly in size (and weight) and contained relatively high frequencies of Ter119-positive EPCs (Figure 9 ). By direct comparison, spleens from EpoR-HM mice failed to support efficient erythroid hyperplasia and also contained lower frequencies of Ter119-positive cells. These outcomes suggest that despite the apparent existence of in vivo compensatory mechanisms, EpoR-HM mice falter in significant ways to support stress erythropoiesis in this hemolytic anemia model. 
Discussion
In type 1 and 2 cytokine receptor systems, JAKs are well established as essential upstream signaling components. 15, 16 Less clear is whether JAK-targeted receptor PY sites also contribute in basic ways to biofunction or perhaps play only modulatory roles. The EpoR system provides an interesting case, and although specific signaling events have been at least tentatively assigned to 8 evolutionarily conserved PY residues, 38 PY-null EpoR forms nonetheless exert substantial erythropoietic activity via JAK2-coupled routes per se when expressed at physiological levels in knock-in 28 and transgenic mouse models. 26, 27 If EpoR PY sites are important, these prior studies predict first that PY-null EpoR-HM function in vivo might be assisted by compensatory mechanisms and, second, that primary erythroid progenitor cells from EpoR-HM mice also might display Epo dose-dependent biosignaling defects in vitro. The present investigations were performed to test these hypotheses. In vitro analyses of Epo-stimulated 3 HdT incorporation, Ter119-positive cell formation, cell surface phosphatidylserine levels, and TUNEL-positive EPCs each revealed Epo dosedependent deficiencies for erythroid progenitor cells from EpoR-HM mice. In addition, serum growth factor activities were elevated in EpoR-HM mice, and capacities to respond to phenylhydrazineinduced anemia were attenuated. Aspects of these findings selected for discussion include (1) insight gained into the functional capacities of this minimal JAK2-coupled PY-null EpoR form through in vitro Epo dosing experiments; (2) major wt-EpoRdirected events that may be attenuated during PY-null EpoR-HM signaling and possibly compensated for during JAK2-only signaling; (3) the possible nature of elevated serum growth factors in EpoR-HM mice; and (4) factors that may limit EpoR-HMmediated stress erythropoiesis.
One primary action of Epo is to inhibit progenitor cell death; this involves, at least in part, Epo-dependent increases in Bcl-xl expression 39 (and roles for Bcl-xl also appear to extend to late stages including reticulocytes). 40 It therefore is possible that the presently observed deficiencies in EpoR-HM-supported EPC proliferation and differentiation may reflect survival defects. For For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From proliferation outcomes, until direct evidence for Epo effects on EPC mitogenesis or cell cycle parameters is generated, this clearly should be considered. Differentiation outcomes, however, can be considered in more specific contexts. With regard first to the stage at which EpoR-HM-dependent EPC formation appears to falter, Ter119 and annexin V binding assays indicate that this is most prominent for a Ter119-positive CD71 low EPC pool and less prominent for a less mature Ter119-positive CD71 high population. Therefore, these EPCs at defined narrow stages are proposed to depend most upon wt-EpoR PY sites and linked pathways. Annexin V binding assays may well reflect differences in survival potential, and this is supported by the outcomes of TUNEL assays for Ter119-positive EpoR-HM versus wt-EpoR EPCs. However, erythroid cell membrane compositions may change during late differentiation, 36 and EpoR-HM-altered differentiation events therefore might also be detected by annexin V binding assays. This does not discount the significance of observed differences between EpoR-HM and wt-EpoR EPCs but does raise possibly interesting questions regarding survival-versus differentiation-based explanations. Questions concerning underlying mechanisms ultimately must be advanced through direct analyses of transduction events (and modulated genes) in purified stage-specific EPCs from EpoR-HM and wt-EpoR mice.
The possible nature of EpoR PY-dependent events that provide an advantage for wt-EpoR EPC development (versus those pathways that support PY-independent EpoR-HM function) is also of interest to consider. EpoR-HM retains juxtamembrane sites for JAK2 binding and PY-null yet JAK2-coupled EpoR forms previously have been shown to efficiently stimulate Myc gene transcription. 41 In 32D cell sublines, a transfected EpoR-HM construct has also been shown to efficiently activate Bcl-x gene transcription, 42 but in FDCW2 cells this was assisted by an EpoR PY343 Stat5 binding site, 43 and Epo-dependent Bcl-x gene expression also has been reported to be attenuated in splenic erythroblasts from Stat5a Ϫ/Ϫ 5b Ϫ/Ϫ mice. 35 Thus, the issue of possible PY343 and Stat5 contributions to EpoR and JAK2-dependent Bcl-x gene expression is presently unresolved (and in EpoR-HM mice, this issue may be complicated further by apparent compensatory mechanisms). Within the EpoR system, JAK2 also has been reported to interact with Vav 44 and to bind and perhaps cofunction with a Src kinase (especially Src or Lyn). 45, 46 Given the substantial bioactivity retained by EpoR-HM, the nature of presently poorly understood EpoR PY-independent JAK2-linked pathways should be interesting to discover. Beyond PY343 and Stat5, an EpoR PY479 site for p85/phosphatidylinositol-3 kinase (PI3K) coupling previously has been shown to likewise efficiently restore function in transduced fetal liver cells 47 and to act through proposed Akt kinase and forkhead transcription factor routes to sustain erythroid progenitor cell survival. 48 Together these studies underline PY343-plus Stat5 and PY479-plus p85/PI3K as prime candidates for supporting the PY-dependent enhanced activity of the wt-EpoR. When considering activities of EpoR-HM (as well as EpoR PY343 or EpoR PY479 forms), it also is important to consider effects of the absence of EpoR PY sites that recruit negatively acting factors (including Cis, SOCS3, and SHP-1) 49, 50 as well as the possible effects of EpoR truncations. 51 In EpoR-HM mice, 2 in vivo perturbations also were discovered: G1E2 cell-based bioassays revealed an increase in serum growth factor activities, and EpoR-HM mice displayed a restricted capacity to mount splenic stress erythropoiesis in response to phenylhydrazine-induced anemia. In EpoR-HM serum, one elevated component may be Epo, and this is an essential factor for the sustained proliferation of the G1E2 cells used in bioassays. However, when FDCW2-EpoR cells were used (versus control parental FDCW2 cells), this EpoR-HM elevated serum activity was not so obviously detected, and this outcome raises questions as to whether levels of additional hematopoietic growth factors might also be increased in EpoR-HM mice (although their nature presently is unknown). Elevated levels of Epo (and/or other growth factors) might also account in part for a previously observed limited capacity of EpoR-HM mice to increase erythropoietic output in response to administered erythropoietin. 28 Finally, the limited ability of EpoR-HM mice to respond to stress-induced anemia with robust splenic erythropoiesis merits consideration. In EpoR-HM mice, this defect exists despite sharp increases in Epo levels that are induced by phenylhydrazine 52 and appears to perhaps be stronger than perturbations in steady-state EPC formation. Stress erythropoiesis is known to have several unique features. This includes roles in early EPCs for glucocorticoid receptor action, 53 emerging roles for bone morphogenetic proteins (BMPs), 54 and heightened roles for SCF action. 55 Whether these, or perhaps other collateral signaling factors, integrate with EpoR PY-coupled events likewise should be interesting to assess in future studies, as should the extent to which other clinically important erythropoietic stress agents might differentially stimulate splenic and marrow erythropoiesis in EpoR-HM (and EpoR-H) knock-in mice. For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From
